Literature DB >> 16838382

Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies.

Yasuhiro Nishiyama1, Sangeeta Karle, Yukie Mitsuda, Hiroaki Taguchi, Stephanie Planque, Maria Salas, Carl Hanson, Sudhir Paul.   

Abstract

Conventional antibodies react with antigens reversibly. We report the formation of unusually stable complexes of HIV gp120 and nucleophilic antibodies raised by immunization with an electrophilic HIV gp120 analog (E-gp120). The stability of the complexes was evident from their very slow dissociation in a nondenaturing solvent (approximate t(1/2) 18.5 days) and their resistance to dissociation by a denaturant commonly employed to disrupt noncovalent protein-protein binding (sodium dodecyl sulfate). Kinetic studies indicated time-dependent and virtually complete progression of the antibody-gp120 complexes from the initial noncovalent state to a poorly dissociable state. The antibodies to E-gp120 displayed improved covalent reactivity with an electrophilic phosphonate probe compared to control antibodies, suggesting their enhanced nucleophilicity. One of the stably binding antibodies neutralized the infectivity of CCR5-dependent primary HIV strains belonging to clades B and C. These findings suggest the feasibility of raising antibodies capable of long-lasting inactivation of antigens by electrophilic immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838382     DOI: 10.1002/jmr.795

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  9 in total

1.  A covalent HIV vaccine: is there hope for the future?

Authors:  Sudhir Paul; Stephanie A Planque; Yasuhiro Nishiyama; Carl V Hanson
Journal:  Future Virol       Date:  2009       Impact factor: 1.831

2.  Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Authors:  Stephanie A Planque; Yukie Mitsuda; Vida Chitsazzadeh; Santhi Gorantla; Larisa Poluektova; Yasuhiro Nishiyama; Christina Ochsenbauer; Mary-Kate Morris; Gopal Sapparapu; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

3.  Specific amyloid β clearance by a catalytic antibody construct.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Sari Sonoda; Yan Lin; Hiroaki Taguchi; Mariko Hara; Steven Kolodziej; Yukie Mitsuda; Veronica Gonzalez; Hameetha B R Sait; Ken-ichiro Fukuchi; Richard J Massey; Robert P Friedland; Brian O'Nuallain; Einar M Sigurdsson; Sudhir Paul
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 4.  Back to the future: covalent epitope-based HIV vaccine development.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama; Miguel Escobar; Carl Hanson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

5.  Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies.

Authors:  Yukie Mitsuda; Stephanie Planque; Mariko Hara; Robert Kyle; Hiroaki Taguchi; Yasuhiro Nishiyama; Sudhir Paul
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

6.  Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.

Authors:  Stephanie Planque; Miguel A Escobar; Keri C Smith; Hiroaki Taguchi; Yasuhiro Nishiyama; Elizabeth Donnachie; Kathleen P Pratt; Sudhir Paul
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

Review 7.  Catalytic antibodies to HIV: physiological role and potential clinical utility.

Authors:  Stephanie Planque; Yasuhiro Nishiyama; Hiroaki Taguchi; Maria Salas; Carl Hanson; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-29       Impact factor: 9.754

8.  Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Yukie Mitsuda; Giovanni Nitti; Hiroaki Taguchi; Lei Jin; Jindrich Symersky; Stephane Boivin; Marcin Sienczyk; Maria Salas; Carl V Hanson; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

9.  CD4 binding determinant mimicry for HIV vaccine design.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  Front Immunol       Date:  2012-12-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.